Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
Research and development	$ 2,600	$ 1,594	$ 5,736	$ 4,366
General and administrative	2,057	1,781	3,761	3,853
Total operating expenses	4,657	3,375	9,497	8,219
Total operating loss	(4,657)	(3,375)	(9,497)	(8,219)
Other income (expense):
Interest income	14	13	28	17
Loss from equity method investment in Galectin Sciences, LLC		(67)		(337)
Total other income (expense)	14	(54)	28	(320)
Net loss	(4,643)	(3,429)	(9,469)	(8,539)
Preferred stock dividends	(230)	(245)	(421)	(485)
Preferred stock accretion	(58)	(57)	(115)	(115)
Net loss applicable to common stockholders	$ (4,931)	$ (3,731)	$ (10,005)	$ (9,139)
Net loss per common share - basic and diluted	$ (0.21)	$ (0.17)	$ (0.43)	$ (0.42)
Weighted average common shares outstanding - basic and diluted	23,731	21,983	23,398	21,570